

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2024 February 14; 30(6): 516-613



## Contents

Weekly Volume 30 Number 6 February 14, 2024

## EDITORIAL

- 516 Diagnostic tools for fecal incontinence: Scoring systems are the crucial first step  
*Liptak P, Duricek M, Banovcin P*
- 523 Unmet needs in biomarkers for autoimmune pancreatitis diagnosis  
*Wang BC, Fan JG*

## REVIEW

- 527 Emerging role of exosomes in ulcerative colitis: Targeting NOD-like receptor family pyrin domain containing 3 inflammasome  
*Li X, Ji LJ, Feng KD, Huang H, Liang MR, Cheng SJ, Meng XD*

## ORIGINAL ARTICLE

## Retrospective Study

- 542 Preoperative prediction of lymphovascular and perineural invasion in gastric cancer using spectral computed tomography imaging and machine learning  
*Ge HT, Chen JW, Wang LL, Zou TX, Zheng B, Liu YF, Xue YJ, Lin WW*

## Clinical Trials Study

- 556 Optimized sequential therapy *vs* 10- and 14-d concomitant therapy for eradicating *Helicobacter pylori*: A randomized clinical trial  
*Seddik H, Benass J, Berrag S, Sair A, Berraida R, Boutallaka H*

## Basic Study

- 565 Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma  
*Wang WP, Shi D, Yun D, Hu J, Wang JF, Liu J, Yang YP, Li MR, Wang JF, Kong DL*

## META-ANALYSIS

- 579 Urea breath test for *Helicobacter pylori* infection in adult dyspeptic patients: A meta-analysis of diagnostic test accuracy  
*Lemos FFB, Castro CT, Silva Luz M, Rocha GR, Correa Santos GL, de Oliveira Silva LG, Calmon MS, Souza CL, Zarpelon-Schutz AC, Teixeira KN, Queiroz DMM, Freire de Melo F*

## CASE REPORT

- 599 Y-Z deformable magnetic ring for the treatment of rectal stricture: A case report and review of literature  
*Zhang MM, Sha HC, Qin YF, Lyu Y, Yan XP*

**LETTER TO THE EDITOR**

- 607** Angiotensin-converting enzyme 2 alleviates liver fibrosis through the renin-angiotensin system  
*Zhao BW, Chen YJ, Zhang RP, Chen YM, Huang BW*
- 610** Endoscopic intramural cystogastrostomy for treatment of peripancreatic fluid collection: A viewpoint from a surgeon  
*Ker CG*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Kok Yang Tan, FRCS (Ed), MBBS, Associate Professor, Chief Doctor, Senior Lecturer, Surgeon, Department of Surgery, Khoo Teck Puat Hospital, Singapore 768828, Singapore. kokyangtan@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

**Production Editor:** Ying-Yi Yuan; **Production Department Director:** Xiang Li; **Editorial Office Director:** Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

February 14, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University  
Biliary Tract Disease Institute, Fudan University

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**POLICY OF CO-AUTHORS**

<https://www.wjgnet.com/bpg/GerInfo/310>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER's OFFICIAL WEBSITE**

<https://www.shca.org.cn>  
<https://www.zs-hospital.sh.cn>



## Urea breath test for *Helicobacter pylori* infection in adult dyspeptic patients: A meta-analysis of diagnostic test accuracy

Fabian Felliipe Bueno Lemos, Caroline Tianeze de Castro, Marcel Silva Luz, Gabriel Reis Rocha, Gabriel Lima Correa Santos, Luís Guilherme de Oliveira Silva, Mariana Santos Calmon, Cláudio Lima Souza, Ana Carla Zarpelon-Schutz, Kádima Nayara Teixeira, Dulciene Maria de Magalhães Queiroz, Fabrício Freire de Melo

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Huang YQ, China

**Received:** November 14, 2023

**Peer-review started:** November 14, 2023

**First decision:** December 5, 2023

**Revised:** December 16, 2023

**Accepted:** January 16, 2024

**Article in press:** January 16, 2024

**Published online:** February 14, 2024



Fabian Felliipe Bueno Lemos, Marcel Silva Luz, Gabriel Reis Rocha, Gabriel Lima Correa Santos, Luís Guilherme de Oliveira Silva, Mariana Santos Calmon, Cláudio Lima Souza, Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil

Caroline Tianeze de Castro, Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador 40110040, Bahia, Brazil

Ana Carla Zarpelon-Schutz, Kádima Nayara Teixeira, Campus Toledo, Universidade Federal do Paraná, Toledo 85919-899, Paraná, Brazil

Dulciene Maria de Magalhães Queiroz, Laboratory of Research in Bacteriology, UFMG, Belo Horizonte 30130-100, Minas Gerais, Brazil

**Corresponding author:** Fabrício Freire de Melo, PhD, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Estrada do Bem Querer, No. 3293-3391- Candeias, Vitória da Conquista 45029-094, Bahia, Brazil. [freiremeloufba@gmail.com](mailto:freiremeloufba@gmail.com)

### Abstract

#### BACKGROUND

*Helicobacter pylori* (*H. pylori*) infection has been well-established as a significant risk factor for several gastrointestinal disorders. The urea breath test (UBT) has emerged as a leading non-invasive method for detecting *H. pylori*. Despite numerous studies confirming its substantial accuracy, the reliability of UBT results is often compromised by inherent limitations. These findings underscore the need for a rigorous statistical synthesis to clarify and reconcile the diagnostic accuracy of the UBT for the diagnosis of *H. pylori* infection.

#### AIM

To determine and compare the diagnostic accuracy of <sup>13</sup>C-UBT and <sup>14</sup>C-UBT for *H. pylori* infection in adult patients with dyspepsia.

#### METHODS

We conducted an independent search of the PubMed/MEDLINE, EMBASE, and Cochrane Central databases until April 2022. Our search included diagnostic accuracy studies that evaluated at least one of the index tests (<sup>13</sup>C-UBT or <sup>14</sup>C-UBT) against a reference standard. We used the QUADAS-2 tool to assess the methodo-

logical quality of the studies. We utilized the bivariate random-effects model to calculate sensitivity, specificity, positive and negative test likelihood ratios (LR+ and LR-), as well as the diagnostic odds ratio (DOR), and their 95% confidence intervals. We conducted subgroup analyses based on urea dosing, time after urea administration, and assessment technique. To investigate a possible threshold effect, we conducted Spearman correlation analysis, and we generated summary receiver operating characteristic (SROC) curves to assess heterogeneity. Finally, we visually inspected a funnel plot and used Egger's test to evaluate publication bias.

## RESULTS

The titles and abstracts of 4621 studies were screened; 79 articles were retrieved and selected for full-text reading. Finally, 60 studies were included in the diagnostic test accuracy meta-analysis. Our analysis demonstrates superior diagnostic accuracy of  $^{13}\text{C}$ -UBT over  $^{14}\text{C}$ -UBT, indicated by higher sensitivity (96.60% *vs* 96.15%), specificity (96.93% *vs* 89.84%), likelihood ratios (LR+ 22.00 *vs* 10.10; LR- 0.05 *vs* 0.06), and area under the curve (AUC; 0.979 *vs* 0.968). Notably,  $^{13}\text{C}$ -UBT's DOR (586.47) significantly outperforms  $^{14}\text{C}$ -UBT (DOR 226.50), making it the preferred diagnostic tool for dyspeptic individuals with *H. pylori* infection. Correlation analysis revealed no threshold effect ( $^{13}\text{C}$ -UBT:  $r = 0.48$ ;  $^{14}\text{C}$ -UBT:  $r = -0.01$ ), and SROC curves showed consistent accuracy. Both  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT showed high AUC values ( $^{13}\text{C}$ -UBT 0.979;  $^{14}\text{C}$ -UBT 0.968) near 1.00, reinforcing their excellent accuracy and endorsing both as reliable diagnostic tools in clinical practice.

## CONCLUSION

In summary, our study has demonstrated that  $^{13}\text{C}$ -UBT has been found to outperform the  $^{14}\text{C}$ -UBT, making it the preferred diagnostic approach. Additionally, our results emphasize the significance of carefully considering urea dosage, assessment timing, and measurement techniques for both tests to enhance diagnostic precision. Nevertheless, it is crucial for researchers and clinicians to evaluate the strengths and limitations of our findings before implementing them in practice.

**Key Words:** *Helicobacter pylori*; Urea breath test; Diagnosis; Diagnostic test accuracy; Meta-analysis

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The urea breath test (UBT) is a pivotal noninvasive method for detecting *Helicobacter pylori* (*H. pylori*); however, its reliability is challenging. This meta-analysis aimed to compare the precision of the  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT in diagnosing *H. pylori* among adults with dyspepsia, providing insights to enhance clinical strategies.

**Citation:** Lemos FFB, Castro CT, Silva Luz M, Rocha GR, Correa Santos GL, de Oliveira Silva LG, Calmon MS, Souza CL, Zarpelon-Schutz AC, Teixeira KN, Queiroz DMM, Freire de Melo F. Urea breath test for *Helicobacter pylori* infection in adult dyspeptic patients: A meta-analysis of diagnostic test accuracy. *World J Gastroenterol* 2024; 30(6): 579-598

**URL:** <https://www.wjgnet.com/1007-9327/full/v30/i6/579.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v30.i6.579>

## INTRODUCTION

*Helicobacter pylori* (*H. pylori*) is a spiral-shaped, gram-negative microaerophilic bacterium that infects approximately 43% of the global population[1]. While the majority of infected individuals remain asymptomatic, chronic gastritis inevitably ensues, leading to a significant burden of morbidity and mortality[2,3]. Adults who are infected with *H. pylori* are at increased risk of developing peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue lymphoma[4-6]. To address this, current guidelines advocate for either a test-and-treat or a scope-and-treat approach in managing uninvestigated dyspepsia, underscoring the importance of timely diagnosis and intervention[7,8].

Diagnostic testing for *H. pylori* infection typically involves two primary categories: Invasive (endoscopic) and non-invasive testing, depending on the application of upper endoscopy[9]. For individuals aged 50 years or older or those with alarm features, the recommended standard diagnostic approach involves upper endoscopy, followed by histopathological examination (HE) or rapid urease test (RUT), and occasionally, culture[8]. In contrast, in dyspeptic patients under 50 years without specific risk factors or alarm symptoms, non-invasive methods such as urea breath testing (UBT), stool antigen testing, and serology are preferred[8,10].

Among non-invasive diagnostic techniques, the UBT has emerged as a prominent method. This approach capitalizes on the urease activity of *H. pylori*, initiating the hydrolysis of ingested urea and consequent release of labeled carbon dioxide[11]. Two commonly utilized isotopic variants,  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT, offer distinctive features. In  $^{13}\text{C}$ -UBT, a stable isotope (carbon-13) is employed, and breath samples are collected and analyzed for labeled carbon dioxide using various methods such as mass spectrometry and infrared spectrometry[12]. This method presents important advantages, notably the absence of ionizing radiation, rendering it suitable for repeated application and applicable in vulnerable populations,



including pregnant women and children[11,13]. In contrast,  $^{14}\text{C}$ -UBT utilizes a radioactive isotope (carbon-14) and primarily relies on scintillation counting for detection[14,15]. Despite its historical use, concerns regarding radiation exposure have diminished its preference in contemporary clinical practice.

In a prior meta-analysis, Ferwana *et al*[16] assessed the diagnostic accuracy of the UBT, encompassing both  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT, for detecting *H. pylori* infection in adult dyspeptic patients. Despite its high accuracy, the reliability of UBT results was constrained by significant unexplained heterogeneity, persisting even after subgroup analysis[16]. This pattern persisted in subsequent studies, with Zhou *et al*[17] finding analogous challenges in calculating pooled estimates of diagnostic accuracy for  $^{14}\text{C}$ -UBT. Moreover, a subsequent systematic review emphasized that the variability in thresholds and reference standards across studies limited the data available for pooling accuracy measures at specific UBT thresholds[18].

These findings underscore the need for a rigorous statistical synthesis to clarify and reconcile the diagnostic accuracy of the UBT for the diagnosis of *H. pylori* infection, addressing challenges identified in prior research. To address this gap in the evidence, we conducted a systematic review and meta-analysis to determine the diagnostic accuracy of the UBT for *H. pylori* infection in adult patients with dyspepsia.

## MATERIALS AND METHODS

This study adhered to the guidelines outlined in the PRISMA-DTA[19]. These guidelines encompass a 27-item checklist and a 3-phase flowchart, both designed to enhance the transparency of systematic review reporting. Accordingly, our study protocol has been officially registered in the PROSPERO database under the registration number CRD42023449854.

### Literature search

This search strategy was designed following the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy (Version 2.0, 2022)[20]. We performed independent, computer-assisted searches of the: (1) PubMed/MEDLINE; (2) EMBASE; and (3) Cochrane Library databases. MeSH (Medical Subject Headings) and Emtree (EMBASE Subject Headings) index terms and free-text words were combined. Search terms included "urea breath test," "breath test," " $^{13}\text{C}$ -urea breath test," " $^{14}\text{C}$ -urea breath test," " $^{13}\text{C}$ -UBT," " $^{14}\text{C}$ -UBT," "*Helicobacter pylori*," "*H. pylori*," and "dyspepsia." Boolean operators (AND, OR) were also used to narrow or broaden the search as required. No language restriction was applied. To identify additional studies, reference lists were also scanned. Finally, we conducted a "citing reference" search (by searching articles which cited the included studies) in PubMed/MEDLINE and EMBASE. Following the search, all identified citations were collated and uploaded into the Rayyan (<https://www.rayyan.ai/>) tool, and all duplicates were removed.

### Selection of studies

Two independent reviewers, Lemos FFB and Calmon MS, screened the references against predefined eligibility criteria. In the case of disagreement, a 3<sup>rd</sup> researcher, Silva Luz M, was consulted. Full-text papers were obtained for references considered relevant. If any study was not retrieved, the authors were contacted. Two authors, Lemos FFB and Correa Santos GL, independently screened the full-text papers against the eligibility criteria. In the case of disagreement, consensus was reached.

We included diagnostic accuracy studies that evaluated at least one of the index tests ( $^{13}\text{C}$ - or  $^{14}\text{C}$ -UBTs) against a reference standard (biopsy fragments followed by culture or HE or RUT and/or not serology/stool antigen-based tests in adult dyspeptic patients. Exclusion criteria were as follows: (1) Studies that enrolled children or adolescents under 18 years of age; (2) studies that included only patients with acute upper gastrointestinal bleeding; (3) studies that enrolled subjects who presented for reasons other than dyspeptic symptoms, complicated dyspeptic cases that need surgery, those who received previous therapy for *H. pylori* within the last 3 months, or long-term use of corticosteroids and immunosuppressant drugs; (4) screening studies; (5) studies that did not report true positive, false positive, false negative, and true negative data and the threshold used for the index tests; (6) case-control studies because these are prone to bias[21]; and (7) full-text articles not available or articles not available in English, Spanish, or Portuguese.

### Data extraction and management

Two review authors, Rocha GR and Correa Santos GL, independently extracted data from each included study using a pre-piloted data extraction form. In case of discrepancies, a 3<sup>rd</sup> researcher, Lemos FFB, was consulted. The extracted data included: (1) Information about the studies, such as the first author, publication year, and country; (2) details about the study design, including the type of study (prospective and retrospective cohort studies, cross-sectional studies, or randomized clinical trials), the reference standards used, blinding of the index test and reference standard, and the flow and timing (retrospective/prospective); (3) participant information, *i.e.*, the total number of participants and population characteristics (age, mean  $\pm$  SD, sex, and disease prevalence); (4) reference standard details, including the time interval between the index test and the reference standard; index test information, including the model ( $^{13}\text{C}$ - or  $^{14}\text{C}$ -UBT), cut-off values, urea dosing, time for measurement after urea administration (min), and measurement technique; and (5) diagnostic accuracy data, including the number of true positives, false positives, false negatives, and true negatives.

### Assessment of methodological quality

Two independent reviewers, Silva Luz M and de Oliveira Silva LG, conducted critical appraisal using the QUADAS-2 tool. In cases of disagreement, they consulted a 3<sup>rd</sup> researcher, Lemos FFB. The QUADAS-2 tool is applied in four phases

[21]: Summarizing the review question, tailoring the tool and producing review-specific guidance, constructing a flow diagram for the primary study, and evaluating bias and applicability. This tool comprises four domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed for the risk of bias, and the first three domains are also evaluated for concerns regarding applicability. It's important to note that "risk of bias" refers to internal validity, *i.e.*, whether there are systematic errors in conducting the study with respect to the specific domain, while "applicability concern" pertains to external validity, *i.e.*, whether there are concerns that the population, index test, or reference standard used in the studies align with the review question. Signaling questions were also included to assist in assessing the risk of bias.

### Statistical analysis and data synthesis

Eligible studies were subjected to data extraction, and we organized the data into  $2 \times 2$  tables. In our analysis, we selected only the optimal threshold values for *H. pylori* positivity in cases where multiple thresholds were presented. We added 0.5 to values equal to zero to ensure computational stability and prevent potential issues[22].

To address the anticipated diversity in meta-analyses of diagnostic accuracy studies, we utilized the random-effects model to calculate sensitivity, specificity, positive and negative test likelihood ratios (LR+ and LR-), as well as the diagnostic odds ratio (DOR)[23]. We also determined the corresponding 95% confidence intervals (95% CIs). The results of the  $^{13}\text{C}$ - and  $^{14}\text{C}$ -UBT are presented separately. Subgroup analyses were conducted with a focus on urea dosing, time for measurement after urea administration (in minutes), and the assessment technique employed. To investigate the possibility of a threshold effect in the analysis, we conducted Spearman correlation analysis. A substantial threshold effect was recognized when the correlation coefficient reached or exceeded 0.6[24].

We performed a bivariate random-effects meta-analysis and generated summary receiver operating characteristic (SROC) curves to visually assess heterogeneity. Furthermore, these curves allowed us to predict accuracy by summarizing diagnostic performance as the area under the curve (AUC)[25]. We categorized accuracy levels as follows: fail (0.50-0.60), poor (0.61-0.70), fair (0.71-0.80), good (0.81-0.90), and excellent (0.91-1.00)[22].

To evaluate publication bias, we conducted a visual inspection of a funnel plot and employed Egger's tests for statistical assessment. The creation of this plot and the assessment of the risk of data due to missing data required a minimum of ten studies.

All analyses were performed using R version 4.2.1, an environment for statistical computing in Vienna, Austria, utilizing the "meta" package (version 6.5-0), "dmetar" package (version 0.1.0), and the "mada" package (version 0.5.11).

## RESULTS

### Study selection

Database searches initially yielded 10902 reports, from which duplicates were removed. No additional references were discovered through alternative search methods. Subsequently, the titles and abstracts of 4621 studies underwent screening, resulting in the retrieval and selection of 79 articles for full-text examination. Ultimately, 60 studies fulfilled the inclusion criteria. The reasons for exclusion were as follows: Incorrect population ( $n = 8$ ), unsuitable reference standard ( $n = 4$ ), insufficient accuracy measures ( $n = 2$ ), missing threshold information ( $n = 2$ ), failure to compare against the reference standard ( $n = 1$ ), writing in a foreign language ( $n = 1$ ), and involvement of the same sample ( $n = 1$ ). Figure 1 illustrates the flow of information through various phases of the systematic review.

### General characteristics of included studies

Among all the studies, 39 (comprising 65%) employed the  $^{13}\text{C}$ -UBT as their primary diagnostic test, featuring a median population size of 200 individuals (lower to upper quartile: 84.5-254). Cross-sectional study design was predominant, making up 97.5% of the total, while only one study (2.5%) adopted a randomized controlled trial approach. For the  $^{13}\text{C}$ -UBT, the median pre-test probability was 51.2% (lower to upper quartile: 47.8-67.6). Various reference standards were used, with the most common being "*H. pylori* culture (HpC) or (HE and RUT)," accounting for 22.5% of cases. Other reference standards included "HE and RUT" (17.5%), "HE" (12.5%), "HE or HpC" (12.5%), "HE or (RUT and serology)" (5%), "RUT" (5%), "HE, HpC, and RUT" (5%), and "HpC" (2.5%). Some studies also combined reference standards, such as "RUT or HE" and "(HE, HpC, RUT) at least two positives," each constituting 2.5% of the sample, as shown in Table 1.

On the other hand, the  $^{14}\text{C}$ -UBT accounted for 35% of the total (21 studies) with a median population size of 108.5 (lower to upper quartile: 63.5-125.5). For the  $^{14}\text{C}$ -UBT, the median pre-test probability was 64.9% (lower to upper quartile: 43.6-73.1). Various reference standards were employed in these studies, with "HE" being the most prevalent, accounting for 38.1% of cases. Other reference standards included "HE and RUT" (14.3%) and "HpC or HE" (9.5%). Some studies also used combinations of reference standards, such as "HE, RUT, Serology (at least two positive)" and "HpC or [HE and (RUT or Gram staining)]," each comprising 4.8% of the sample, as detailed in Table 2.

### Methodological quality assessment

Supplementary Figure 1 and Figure 2 provide a visual representation of the comprehensive methodological quality assessment of the included studies. In the patient selection domain, 22 studies (35.5%) were categorized as having a low risk of bias, 36 studies (58.1%) were associated with a high risk of bias, and 2 studies (3.2%) were considered to have an unclear risk of bias. In terms of patient selection applicability, 40 studies (64.5%) exhibited low concern, 17 studies (27.4%) showed high concern, and 3 studies (4.8%) had unclear concern.



**Table 1 Characteristics of the included studies that assessed the diagnostic test accuracy of the <sup>13</sup>C-urea breath test**

Ref.	Country	Design	Population, <i>n</i>	Prevalence (%)	Reference standard	Index test (model)	Optimal cut-off	Urea dosing (mg)	Time after administration (min)	Measurement technique	TP	FP	TN	FN
Wang <i>et al</i> [29], 2021	China	Cross-sectional	217	65.9	HE	<sup>13</sup> C-UBT	10.4‰ DOB	50	30	IS	120	14	60	23
Alzoubi <i>et al</i> [33], 2020	Jordan	Cross-sectional	30	56.7	RUT or HE	<sup>13</sup> C-UBT	4‰ DOB	75	30	IS	16	3	10	1
Nawacki <i>et al</i> [34], 2018	Poland	Cross-sectional	50	36.0	RUT	<sup>13</sup> C-UBT	9.5‰ DOB	NR	30	IS	16	0	32	2
Som <i>et al</i> [27], 2014	India	Cross-sectional	83	59.0	RUT	<sup>13</sup> C-UBT	1.47‰	75	Multiple times	ICOS	49	0	34	0
Bruden <i>et al</i> [35], 2011	United States	Cross-sectional	280	53.2	HE or (HpC and RUT)	<sup>13</sup> C-UBT	7 DOB	NR	NR	NR	139	16	115	10
Peng <i>et al</i> [36], 2009	Taiwan	Cross-sectional	100	53.0	HpC or (HE and RUT)	<sup>13</sup> C-UBT	4.8‰ DOB	100	15	IS	53	7	40	0
Jordaan <i>et al</i> [37], 2008	South Africa	Cross-sectional	103	58.3	HE	<sup>13</sup> C-UBT	4.5‰ DOB	75	NR	GCMS	55	3	40	5
Gatta <i>et al</i> [26], 2006	Italy	RCT	100	43.0	HE and RUT	<sup>13</sup> C-UBT	4.40‰-6.26‰ DOB	25	30	IRMS	43	0	57	0
Peng <i>et al</i> [38], 2005	Taiwan	Cross-sectional	50	36.0	HpC or (HE and RUT)	<sup>13</sup> C-UBT	5‰ DOB	100	15	IRMS	18	0	32	0
Kato <i>et al</i> [39], 2004	Japan	Cross-sectional	254	51.1	HpC or (HE and RUT)	<sup>13</sup> C-UBT	2.5‰ DOB	100	20	IRMS	252	5	242	6
Ohara <i>et al</i> [40], 2004	Japan	Cross-sectional	254	51.2	HpC or (HE and RUT)	<sup>13</sup> C-UBT	2.5‰ DOB	100	Multiple times	IRMS	127	2	122	3
Chen <i>et al</i> [41], 2003	Taiwan	Cross-sectional	554	66.6	HpC or (HE and RUT)	<sup>13</sup> C-UBT	3.5‰ DOB	100	20	IS	361	6	179	8
Valdepérez <i>et al</i> [42], 2003	Spain	Cross-sectional	85	76.8	HE and RUT	<sup>13</sup> C-UBT	NR	100	30	NR	61	0	19	2
Gatta <i>et al</i> [43], 2003	Italy	Cross-sectional	200	56.5	HpC or (HE and RUT)	<sup>13</sup> C-UBT	3.11‰-6.84‰ DOB	75	30	IRMS	113	0	87	0
Wong <i>et al</i> [44], 2003	China	Cross-sectional	200	49.5	HE and RUT	<sup>13</sup> C-UBT	2.1‰ DOB	50	20	IRMS	99	0	101	0
Ng <i>et al</i> [45], 2002	China	Cross-sectional	213	54.9	HE and RUT	<sup>13</sup> C-UBT	4.0‰-6.5‰ DOB	75	30	IRMS	112	2	94	5

Wong <i>et al</i> [46], 2001	China	Cross-sectional	101	48.1	HE and RUT	<sup>13</sup> C-UBT	7.0-8.0‰ DOB	50	20	IRMS	99	4	103	0
Wong <i>et al</i> [47], 2001	China	Cross-sectional	294	55.4	HE, HpC, CLO (RUT), in-house RUT, PCR, UBT (at least four positive)	<sup>13</sup> C-UBT	5‰ DOB	75	30	IRMS	151	4	127	12
Shirin <i>et al</i> [48], 2001	United States	Cross-sectional	97	47.4	HE and RUT	<sup>13</sup> C-UBT	Positive: > 6‰ DOB (> 2 points)/negative: < 3‰ DOB (> 2 points)	75	5	MCS	45	2	49	1
Pilotto <i>et al</i> [49], 2000	Italy	Cross-sectional	96	51.0	HE, HpC, and RUT	<sup>13</sup> C-UBT	5‰ DOB	100	30	IRMS	49	2	45	0
Sheu <i>et al</i> [50], 2000	Taiwan	Cross-sectional	177	47.5	HE or HpC	<sup>13</sup> C-UBT	3.5 DOB	50	15	IS	81	1	92	3
Wong <i>et al</i> [51], 2000	China	Cross-sectional	202	56.4	HE and RUT	<sup>13</sup> C-UBT	4.5‰ DOB	75	30	IRMS	108	2	86	6
Hahn <i>et al</i> [52], 2000	United States	Cross-sectional	67	6.0	HE and at least two positives of (definitive presence of <i>H. pylori</i> organisms in HE, UBT, Serology)	<sup>13</sup> C-UBT	2.4‰ DOB	125	30	IRMS	4	9	54	0
Chen <i>et al</i> [53], 2000	Japan	Cross-sectional	162	83.3	HE and Serology	<sup>13</sup> C-UBT	2.5‰ DOB	100	20	IRMS	135	1	26	0
Peng <i>et al</i> [54], 2000	Taiwan	Cross-sectional	136	59.6	HpC or (HE and RUT)	<sup>13</sup> C-UBT	4.8‰ DOB	100	15	IRMS	76	6	49	5
Riepl <i>et al</i> [55], 2000	Germany	Cross-sectional	84	35.7	HE, HpC, and RUT	<sup>13</sup> C-UBT	6.5‰ DOB	75	15	IS	30	0	54	0
D'Ellos <i>et al</i> [56], 2000	Italy	Cross-sectional	256	45.3	HE	<sup>13</sup> C-UBT	4‰ DOB	75	30	IRMS	113	2	138	3
van der Hulst <i>et al</i> [57], 1999	Italy	Cross-sectional	544	52.2	HE or HpC	<sup>13</sup> C-UBT	7.5‰ DOB ± 0.8	100	30	LOGES	260	21	239	24
Leodolter <i>et al</i> [58], 1999	Germany	Cross-sectional	320	48.1	HpC or (HE and RUT)	<sup>13</sup> C-UBT	4‰ DOB	75	30	IRMS	142	2	164	12
Mock <i>et al</i> [59], 1999	Canada	Cross-sectional	98	19.8	HE or (RUT and Serology)	<sup>13</sup> C-UBT	3‰ DOB	75	30	IRMS	17	2	75	2
Mock <i>et al</i> [59], 1999	Korea	Cross-sectional	107	68.2	HE or (RUT and Serology)	<sup>13</sup> C-UBT	3‰ DOB	75	30	IRMS	69	1	33	4
Perri <i>et al</i> [60], 1998	Belgium	Cross-sectional	172	73.3	HE or HpC	<sup>13</sup> C-UBT	1.15‰ DOB	75	60	IRMS	121	1	45	5
Ohara <i>et al</i> [61], 1998	Japan	Cross-sectional	213	77.5	HpC or at least two positives of (HE, RUT, Serology)	<sup>13</sup> C-UBT	2.5‰ DOB	100	20	IRMS	162	1	47	3

Leodolter <i>et al</i> [62], 1998	Germany	Cross-sectional	40	50.0	HpC or (HE and RUT)	<sup>13</sup> C-UBT	4‰ DOB	75	10	IRMS	20	0	20	0
Andersen <i>et al</i> [63], 1998	Denmark	Cross-sectional	97	54.6	HE or HpC	<sup>13</sup> C-UBT	5‰ DOB	100	Multiple times	IRMS	46	4	40	7
Ellenrieder <i>et al</i> [64], 1997	Germany	Cross-sectional	132	43.2	(HE, HpC, RUT) at least two positives	<sup>13</sup> C-UBT	3.5‰ DOB	NR	30	IS	52	8	67	5
Epple <i>et al</i> [65], 1997	Germany	Cross-sectional	126	61.1	HE	<sup>13</sup> C-UBT	1.3‰ DOB	75	30	IRMS	74	7	42	3
Labenz <i>et al</i> [66], 1996	Germany	Cross-sectional	70	67.1	HE or HpC	<sup>13</sup> C-UBT	4‰ DOB	75	30	IRMS	46	0	23	1
Logan <i>et al</i> [67], 1991	England	Cross-sectional	56	68.0	HE	<sup>13</sup> C-UBT	4.5‰ DOB	125	Multiple times	IRMS	32	1	15	2
Dill <i>et al</i> [68], 1990	Scotland	Cross-sectional	69	49.3	HpC	<sup>13</sup> C-UBT	3‰ c-PDR	250	20	IRMS	33	0	35	1

CLO: Campylobacter-like organism; GCMS: Gas chromatography-mass spectrometry; HE: Histopathological examination; HpC: *Helicobacter pylori* culture; ICOS: Integrated Cavity Output Spectrometry; IRMS: Isotope ratio mass spectrometry; IS: Infrared spectrometry; LOGES: Laser opto-galvanic Effect Spectroscopy; MCS: Molecular correlation spectrometry; NR: Not reported; RUT: Rapid urease test; UBT: Urea breath test; DOB: Delta over baseline; RCT: Randomized clinical trial.

Within the index test selection domain, 33 studies (53.2%) were rated as having a low risk of bias, 26 studies (41.9%) were identified with a high risk, and 1 study (1.6%) had an unclear risk of bias. Concerning index test applicability, 57 studies (91.9%) displayed low concern, while 3 studies (4.8%) raised high concern.

In the reference standard domain, 47 studies (75.8%) demonstrated a low risk of bias, 12 studies (19.4%) showed a high risk of bias, and 1 study (1.6%) had an unclear risk of bias. Notably, none of the studies raised concerns about the applicability of the reference standard.

Lastly, in the flow and timing domain, 23 studies (37.1%) were associated with a low risk of bias, 23 studies (37.1%) exhibited a high risk of bias, and 7 studies (11.3%) had an unclear risk of bias.

### Overall accuracy of the <sup>13</sup>C-UBT

The <sup>13</sup>C-UBT test was evaluated for its diagnostic accuracy in 39 studies *via* a comprehensive meta-analysis. The results demonstrated a high sensitivity of 96.60% (95%CI: 95.64-97.56; *P* value < 0.01; *I*<sup>2</sup> = 65.0%) and an equally impressive specificity of 96.93% (95%CI: 96.04-97.82; *P* value < 0.01; *I*<sup>2</sup> = 58.0%) for this test (Figure 3). Additionally, the DOR was calculated at 586.47 (95%CI: 340.03-1011.51), with a positive likelihood ratio (LR+) of 22.00 (95%CI: 15.60-30.10) and a negative likelihood ratio (LR-) of 0.05 (95%CI: 0.04-0.06) as presented in Supplementary Table 1.

### Subgroup analysis of the <sup>13</sup>C-UBT - Urea dosing

Among the thirty-six studies that documented the urea dosage, a 25 mg urea dose demonstrated notably high sensitivity (98.85%; 95%CI: 95.68-100.00) and specificity (99.13%; 95%CI: 96.73-100.00), as illustrated in Supplementary Figure 2. Increasing the urea dose to 50 mg across four studies resulted in a sensitivity of 95.28% (95%CI: 88.51-100.00) and a specificity of 94.91% (95%CI: 87.67-100.00). Seventeen studies explored the use of 75 mg of urea in the <sup>13</sup>C-UBT, revealing

**Table 2 Characteristics of the included studies that assessed the diagnostic test accuracy of the <sup>14</sup>C-urea breath test**

Ref.	Country	Design	Population, n	Prevalence (%)	Reference standard	Index test (model)	Optimal cut-off	Urea dosing (μCi)	Time after administration (min)	Measurement technique	TP	TN	FP	FN
Han <i>et al</i> [30], 2023	China	Cross-sectional	205	42.4	HE and RUT	<sup>14</sup> C-UBT	100 dpm	0.75	20	SC	83	3	115	4
Wang <i>et al</i> [29], 2021	China	Cross-sectional	267	71.9	HE	<sup>14</sup> C-UBT	238 dpm	0.75	25	NR	158	12	63	34
Miftahussurur [69], 2021	Indonesia	Cross-sectional	55	23.6	HE	<sup>14</sup> C-UBT	57 cpm	1	10	HA	12	1	41	1
Cosgun <i>et al</i> [70], 2016	Turkey	Cross-sectional	126	92.1	HpC or HE	<sup>14</sup> C-UBT	NR	1	10	HA	112	7	3	4
Atli <i>et al</i> [71], 2012	Turkey	Cross-sectional	100	35.0	HE	<sup>14</sup> C-UBT	Positive: > 50 cpm/suspicious: 25-50 cpm /negative: < 25 dpm	1	10	HA	32	4	61	3
Alarcón-Rivera <i>et al</i> [72], 2011	Mexico	Cross-sectional	84	70.2	HE	<sup>14</sup> C-UBT	Positive: > 50 ppm/indeterminate: 25-50 ppm/negative: < 25 ppm	1	10-15	HA	56	1	24	3
Mansour-Ghanaei <i>et al</i> [73], 2011	Iran	Cross-sectional	125	56.8	HE, RUT, Serology (at least two positive)	<sup>14</sup> C-UBT	50 cpm	1	15	HA	67	0	54	4
Ozdemir <i>et al</i> [74], 2008	Turkey	Cross-sectional	89	66.3	HE, RUT, PCR (at least two positive)	<sup>14</sup> C-UBT	Positive: > 50 cpm/equivocal: 25-50 cpm; negative: < 25 dpm	1	10	HA	57	0	30	2
Rasool <i>et al</i> [75], 2007	Pakistan	Cross-sectional	94	64.9	RUT	<sup>14</sup> C-UBT	50 cpm	1	10	β-SC	60	3	30	1
Gurbuz <i>et al</i> [76], 2005	Turkey	Cross-sectional	65	44.6	HE	<sup>14</sup> C-UBT	Positive: > 50 cpm/suspicious: 25-50 cpm /negative: < 25 dpm	1	10	HA	26	8	28	3
Gatta <i>et al</i> [31], 2003	Italy	Cross-sectional	117	65.0	HpC or (HE and RUT)	<sup>14</sup> C-UBT	130-136 dpm (dpm at sample-dpm at T0)	1	12.5	LSC	73	2	39	3
González <i>et al</i> [77], 2003	Chile	Cross-sectional	NR	71.9	Two or more positives	<sup>14</sup> C-UBT	200 dpm	1	10	LSC	61	14	11	3
Oztürk <i>et al</i> [78], 2009	Turkey	Cross-sectional	75	65.8	HE	<sup>14</sup> C-UBT	100 dpm	1	10	LSC	48	5	20	0
Gomes <i>et al</i> [79], 2002	Brazil	Cross-sectional	137	83.9	HE and RUT	<sup>14</sup> C-UBT	1000 cpm	5	15	LSC	114	1	21	1
Desroches <i>et al</i> [80], 1997	Canada	Cross-sectional	56	80.4	HE or HpC	<sup>14</sup> C-UBT	0.33‰ AS ( <sup>14</sup> CO <sub>2</sub> specific activity)	5	20	LSC	44	0	11	1
Allardyce <i>et al</i>	New	Cross-	63	34.9	HE and RUT	<sup>14</sup> C-UBT	49 dpm	1	30	β-SC	22	2	39	0

[81], 1997	Zealand	sectional												
Faigel <i>et al</i> [82], 1996	United States	Cross-sectional	50	42.6	HE or RUT	<sup>14</sup> C-UBT	Positive: > 200 dpm in any sample/borderline: 100-200 dpm (as the peak count)/negative: < 100 dpm (in all samples)	1	Multiple times	LSC	18	1	26	2
Goh <i>et al</i> [83], 1995	Malaysia	Cross-sectional	63	50.8	HpC or [HE and (RUT or Gram staining)]	<sup>14</sup> C-UBT	1275 dpm	5	15	LSC	32	0	31	0
Kao <i>et al</i> [84], 1993	China	Cross-sectional	184	53.8	HpC or RUT	<sup>14</sup> C-UBT	150‰	5	10	LSC	99	14	71	0
Vivas <i>et al</i> [85], 1993	Venezuela	Cross-sectional	15	53.3	HE	<sup>14</sup> C-UBT	100 dpm	1	20	β-SC	8	1	6	0
Novis <i>et al</i> [28], 1991	Israel	Cross-sectional	64	80.3	HE	<sup>14</sup> C-UBT	4,7‰	10	Multiple times	LSC	59	3	12	2

CLO: Campylobacter-like organism; HA: Heliprobe Analyser; HE: histopathological examination; HpC: *Helicobacter pylori* culture; LSC: Liquid scintillation counting; NR: Not reported; RUT: Rapid urease test; SC: Solid scintillation counting; UBT: Urea breath test; β-SC: Beta-scintillation counting.


a sensitivity of 96.47% (95%CI: 95.14-97.79) and a specificity of 98.33% (95%CI: 97.59-99.07). In cases where 100 mg of urea was used (in 12 studies), the <sup>13</sup>C-UBT demonstrated a sensitivity of 97.31% (95%CI: 95.92-98.70) and a specificity of 96.08% (95%CI: 94.34-97.82). Two studies employing 125 mg of urea showed a sensitivity of 93.76% (95%CI: 86.13-100.00) and a specificity of 88.66% (95%CI: 81.07-96.25). Lastly, in a single study using 250 mg of urea, the <sup>13</sup>C-UBT exhibited a sensitivity of 97.06% (95%CI: 91.38-100.00) and a specificity of 98.59% (95%CI: 94.72-100.00).

### Subgroup analysis of the <sup>13</sup>C-UBT - Time for assessment after urea administration


Among the 36 studies that provided information on the time after urea administration, optimal sensitivity (98.87%; 95%CI: 98.14-99.60) and specificity (98.14%; 95%CI: 96.98-99.30) were achieved when the assessment was conducted 20 min after urea administration [in 7 studies (Supplementary Figure 3)]. Notably, there were variations in sensitivity and specificity for different time intervals following urea administration.

For tests conducted 5 min post-urea administration (in one study), sensitivity was 97.83% (95%CI: 93.61-100.0), and specificity was 96.08% (95%CI: 90.75-100.00). Tests performed 10 min after urea administration (based on one study) yielded a sensitivity of 97.56% (95%CI: 90.88-100.0) and a specificity of 97.56% (95%CI: 90.88-100.00).

Similarly, in the case of tests carried out at 15 min post-urea administration (as reported in five studies), sensitivity averaged at 97.61% (95%CI: 95.68-99.55), with specificity at 95.85% (95%CI: 91.33-100.00). Longer intervals, such as 30 min and 60 min, as well as tests conducted at multiple time points after urea administration, displayed some variability. For instance, tests performed 30 min after urea administration (in 19 studies) had a sensitivity of 95.15% (95%CI: 93.30-96.92) and a specificity of 96.18% (95%CI: 94.48-97.87). A single study conducting tests 60 min post-urea administration reported a sensitivity of 96.03% (95%CI: 92.62-99.44) and a specificity of 97.83% (95%CI: 93.61-100.00). In the case of four studies investigating multiple time points after urea administration, the sensitivity was 96.13% (95%CI: 92.13-100.0), and the specificity was 97.95% (95%CI: 96.08-99.81).



**Figure 1 PRISMA 2020 flow diagram.** This flowchart delineates the progression of information throughout various phases of the systematic review, illustrating the quantities of records identified, included, and excluded, along with the rationales for study exclusion.



**Figure 2 QUADAS-2 methodological quality graph.** The QUADAS-2 methodological quality graph consists of four sections, each representing one of the key domains assessed.

### Subgroup analysis of the $^{13}\text{C}$ -UBT - Assessment technique


In our analysis of 38 studies that included data on the  $^{13}\text{C}$ -UBT assessment technique, Integrated Cavity Output Spectrometry (ICOS) for measuring  $\text{CO}_2$  Isotope Ratios exhibited exceptional performance. ICOS demonstrated a sensitivity of 98.99% (95%CI: 96.20-100.00) and a specificity of 98.55% (95%CI: 94.56-100.00), as visualized in [Supplementary Figure 4](#). In contrast, Infrared spectrometry, assessed in 8 studies, displayed a sensitivity of 94.72% (95%CI: 90.91-98.54) and a specificity of 98.55% (95%CI: 88.17-98.22).

Gas chromatography-mass spectrometry, investigated in a single study, yielded a sensitivity of 91.67% (95%CI: 84.67-98.66) and a specificity of 93.02% (95%CI: 85.41-100.00). Isotope-ratio mass spectrometry, scrutinized in 17 studies, demonstrated a sensitivity of 97.37% (95%CI: 96.45-98.28) and a specificity of 98.38% (95%CI: 84.67-98.66). Molecular correlation spectrometry, examined in a solitary study, exhibited a sensitivity of 97.83% (95%CI: 93.61-100.00) and a specificity of 96.08% (95%CI: 90.75-100.00). Similarly, Laser opto-galvanic effect spectroscopy, reported in one study, recorded a sensitivity of 91.65% (95%CI: 88.31-94.78) and a specificity of 91.92% (95%CI: 88.61-98.21).

### Overall accuracy of the $^{14}\text{C}$ -UBT

A total of 21 studies investigated the diagnostic accuracy of the  $^{14}\text{C}$ -UBT, revealing a combined sensitivity of 96.15% (95%CI: 94.47-97.82;  $P$  value < 0.01;  $I^2 = 62.0\%$ ) and specificity of 89.84% (95%CI: 84.90-94.77;  $P$  value < 0.01;  $I^2 = 78.0\%$ ), as depicted in [Figure 4](#). Within this dataset, a DOR of 226.50 (95%CI: 102.57-500.15), a positive likelihood ratio (LR+) of 10.10 (95%CI: 5.74-16.90), and a negative likelihood ratio (LR-) of 0.06 (95%CI: 0.04-0.08) were observed, as summarized in [Supplementary Table 1](#).





**Figure 3** Forest plot for studies based on the  $^{13}\text{C}$ -urea breath test for *Helicobacter pylori* infection in dyspeptic patients. A: Forest plot for overall sensitivity; B: Forest plot for overall specificity. 95%CI: 95% confidence interval.

### Subgroup analysis of the $^{14}\text{C}$ -UBT - Urea dosing

Twenty-one studies investigated varying urea dosages in the context of the  $^{14}\text{C}$ -UBT. Among these, the use of a 5  $\mu\text{Ci}$  marked urea dose, as examined in four studies, demonstrated exceptional sensitivity (99.21%; 95%CI: 98.20-100.00) and specificity (93.43%; 95%CI: 86.45-100.00), as depicted in [Supplementary Figure 5](#). Elevating the urea dose to 10  $\mu\text{Ci}$ , as explored in a single study, resulted in a sensitivity of 96.72% (95%CI: 92.15-100.00) and a specificity of 80.00% (95%CI: 56.76-100.00). Conversely, when employing 1  $\mu\text{Ci}$  of marked urea (in 14 studies), the  $^{14}\text{C}$ -UBT exhibited a sensitivity of 96.78% (95%CI: 95.46-98.09) and a specificity of 87.19% (95%CI: 59.76-95.81). Lastly, two studies using 0.75  $\mu\text{Ci}$  of urea reported a sensitivity of 88.94% (95%CI: 76.10-100.00) and a specificity of 91.32% (95%CI: 78.18-100.00).

### Subgroup analysis of the $^{14}\text{C}$ -UBT - Time for measurement after marked urea administration


When considering the time for measurement after urea administration, an analysis of all included studies consistently revealed the highest sensitivity (98.39%; 95%CI: 96.36-100.00) and specificity (98.71%; 95%CI: 96.58-100.00) when the tests were conducted 15 minutes after urea administration, as illustrated in [Supplementary Figure 6](#).

In studies conducted shortly after urea administration (within 10 minutes,  $n = 9$ ), the sensitivity was consistently high at 97.83% (95%CI: 96.34-99.33), while specificity was somewhat lower at 79.90% (95%CI: 66.15-93.65). A single study, conducted at 12.5 minutes post-administration, reported a sensitivity of 96.05% (95%CI: 91.67-100.00) and a specificity of 95.12% (95%CI: 88.53-100.00). Studies conducted between 10- and 15-minutes post-urea administration ( $n = 3$ ) showed a sensitivity of 94.92% (95%CI: 89.31-100.00) and a specificity of 96.00% (95%CI: 88.32-100.00).

However, longer intervals (20, 25, and 30 min), as well as tests conducted at various time points after urea administration, exhibited more variability. For instance, studies conducted at 20 min post-administration ( $n = 3$ ) showed a sensitivity of 96.52% (95%CI: 93.50-99.55) and a specificity of 97.23% (95%CI: 94.48-99.97). A single study conducted at 25 min post-urea administration reported a sensitivity of 82.29% (95%CI: 76.89-87.69) and a specificity of 84.00% (95%CI: 75.70-92.30). A study conducted at 30 minutes post-administration yielded a sensitivity of 97.78% (95%CI: 91.69-100.00) and a specificity of 95.12% (95%CI: 88.53-100.00). In the case of two studies that investigated multiple time points after urea administration, the sensitivity was 96.03% (95%CI: 91.79-100.00), and the specificity was 91.02% (95%CI: 76.07-100.00).

### Subgroup analysis of the $^{14}\text{C}$ -UBT - Assessment technique

In the assessment of 20 studies with available data on the assessment technique, it was observed that liquid scintillation counting yielded a higher sensitivity of 98.79% (95%CI: 97.90-99.69) while maintaining a specificity of 87.24% (95%CI: 77.69-96.79). Conversely, Solid Scintillation UBT (scintillation counting) demonstrated higher specificity, reaching 97.46% (95%CI: 94.62-100.00), with a sensitivity of 95.40% (95%CI: 91.00-99.80), as illustrated in [Supplementary Figure 7](#).



**Figure 4** Forest plot for studies based on the  $^{14}\text{C}$ -urea breath test for *Helicobacter pylori* infection in dyspeptic patients by time after urea administration. A: Forest plot for overall sensitivity; B: Forest plot for overall specificity. 95%CI: 95% confidence interval.


In contrast, the Heliprobe Analyser, assessed in 7 studies, displayed a sensitivity of 95.41% (95%CI: 93.32-97.50) and a specificity of 88.10% (95%CI: 74.43-100.00). Ultimately, the use of Beta-scintillation counter for the assessment of  $^{14}\text{C}$ -UBT resulted in a sensitivity of 98.11% (95%CI: 95.33-100.00) and a specificity of 93.47% (95%CI: 88.11-98.82).

### Threshold effect and SROC curve

Spearman's correlation analysis for studies evaluating  $^{13}\text{C}$ -UBT revealed a correlation coefficient ( $r$ ) of 0.48, indicating the absence of a threshold effect. Similarly,  $^{14}\text{C}$ -UBT studies exhibited a negligible correlation ( $r = -0.01$ ), also suggesting the absence of a threshold effect. Visual inspection of the SROC curves did not reveal any significant heterogeneity. Both the  $^{13}\text{C}$ -UBT (AUC = 0.979; Figure 5A) and the  $^{14}\text{C}$ -UBT (AUC = 0.968; Figure 5B) displayed excellent diagnostic accuracy.

### Publication bias

The funnel plot visualization exposed asymmetry in both the  $^{13}\text{C}$ -UBT (Figure 6A) and  $^{14}\text{C}$ -UBT (Figure 6B) models. Additionally, Egger's test confirmed the presence of publication bias in both tests. The intercept was 2.54 with a  $P$  value  $< 0.001$  for  $^{13}\text{C}$ -UBT and 3.04 with a  $P$  value  $< 0.001$  for  $^{14}\text{C}$ -UBT.



**Figure 5 Summary operating characteristics curve curves for studies based on the  $^{13}\text{C}$ -urea breath test and the  $^{14}\text{C}$ -urea breath test for *Helicobacter pylori* infection in dyspeptic patients.** The summary operating characteristics curve (SROC) curve is a graphical representation that combines sensitivity and specificity data from multiple studies or diagnostic tests. It illustrates how these measures change with different threshold settings or study parameters. The curve is accompanied by the area under the curve (AUC), which provides a quantitative assessment of the test's overall performance. A higher AUC value indicates better discriminatory ability across tested thresholds. Furthermore, the diagnostic odds ratio (DOR) is derived from the ROC curve and offers an evaluation of the test's diagnostic precision. A higher DOR signifies stronger discriminatory power, reflecting the odds of a positive test result in individuals with the condition compared to those without it. A: SROC curve for studies based on the  $^{13}\text{C}$ -urea breath test (UBT) for *Helicobacter pylori* (*H. pylori*) infection in dyspeptic patients; B: SROC curve for studies based on the  $^{14}\text{C}$ -UBT for *H. pylori* infection in dyspeptic patients. SROC: Summary operating characteristics curve; AUC: Area under the curve; DOR: Diagnostic odds ratio.


## DISCUSSION

### Insights from $^{13}\text{C}$ - and $^{14}\text{C}$ -UBT performance analysis

Our analysis has revealed that the  $^{13}\text{C}$ -UBT outperforms the  $^{14}\text{C}$ -UBT in terms of diagnostic accuracy, as evidenced by the following values: DOR, Likelihood Ratios (LR+ and LR-), and AUC values. Specifically, the  $^{13}\text{C}$ -UBT has sensitivity and specificity values of 96.60% (95%CI: 95.64-97.56;  $P$  value < 0.01;  $I^2$  = 65.0%) and 96.93% (95%CI: 96.04-97.82;  $P$  value < 0.01;  $I^2$  = 58.0%), respectively. In contrast, the  $^{14}\text{C}$ -UBT has sensitivity and specificity values of 96.15% (95%CI: 94.47-97.82;  $P$  value < 0.01;  $I^2$  = 62.0%) and 89.84% (95%CI: 84.90-94.77;  $P$  value < 0.01;  $I^2$  = 78.0%). The LR+ values for the  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT are 22.00 and 10.10, respectively, indicating the likelihood of positive results in individuals with *H. pylori* infection. Conversely, the LR- values, suggesting a reduced likelihood of negative test results for individuals with the infection, are 0.05 for the  $^{13}\text{C}$ -UBT and 0.06 for the  $^{14}\text{C}$ -UBT.

Furthermore, the DOR values show a substantial difference between the two tests. The  $^{13}\text{C}$ -UBT yields a significantly higher DOR of 586.47 compared to the  $^{14}\text{C}$ -UBT's DOR of 226.50. These results indicate that the  $^{13}\text{C}$ -UBT is statistically superior at distinguishing dyspeptic individuals with and without *H. pylori* infection, making it the preferred diagnostic tool in this clinical context.

Finally, it is essential to emphasize that our correlation analysis, utilizing both the  $^{13}\text{C}$ -UBT ( $r$  = 0.48) and the  $^{14}\text{C}$ -UBT ( $r$  = -0.01), yielded no evidence of a threshold effect. Visual examination of the SROC curves revealed no heterogeneity, indicating consistent accuracy assessments across the studies. Additionally, both the  $^{13}\text{C}$ -UBT and the  $^{14}\text{C}$ -UBT displayed remarkably high AUC values: 0.979 for the  $^{13}\text{C}$ -UBT and 0.968 for the  $^{14}\text{C}$ -UBT, which approaching 1.00 reinforces the excellent accuracy of these tests in detecting *H. pylori* infection in individuals with dyspepsia. These findings strongly support the reliability of the  $^{13}\text{C}$ -UBT and the  $^{14}\text{C}$ -UBT as valuable diagnostic tools in clinical practice.



DOI: 10.3748/wjg.v30.i6.579 Copyright ©The Author(s) 2024.

**Figure 6** Funnel plots for studies based on  $^{13}\text{C}$ -urea breath test and  $^{14}\text{C}$ -urea breath test for *Helicobacter pylori* infection in dyspeptic patients. A: Funnel plot for studies based on  $^{13}\text{C}$ -urea breath test (UBT); B: Funnel plot for studies based on  $^{14}\text{C}$ -UBT.

### **$^{13}\text{C}$ -UBT performance: Urea dose, assessment timing, and measurement technique selection**

Our analysis highlights the critical importance of selecting the appropriate urea dose when conducting the  $^{13}\text{C}$ -UBT for diagnosing *H. pylori* infection. While the 25 mg urea dose displays the highest sensitivity (98.85%) and specificity (99.13%), concerns regarding the generalizability of these results arise due to the fact that these findings are primarily based on a single study[26]. In contrast, the use of 75 mg and 100 mg doses is supported by a larger body of evidence, maintaining excellent diagnostic accuracy with sensitivity and specificity exceeding 96%. Conversely, higher doses, such as 125 mg or 250 mg, exhibit a modest reduction in accuracy, particularly in terms of specificity. These findings strongly advocate for the consideration of 75 mg and 100 mg doses when aiming to optimize both sensitivity and specificity.

A crucial factor affecting the performance of the  $^{13}\text{C}$ -UBT is the timing of the assessment following urea administration. Our observations reveal that the optimal sensitivity and specificity, both exceeding 98%, are achieved at the 20-minute mark post-urea administration. Tests conducted at shorter intervals, such as 5 min and 10 min, also demonstrate high sensitivity and specificity, albeit slightly lower than the 20-min assessment. Conversely, assessments at 15 min maintain excellent accuracy, with sensitivity close to 98% and specificity around 95%. However, assessments at longer intervals, such as 30 min, 60 min, and multiple time points, exhibit some variability, with sensitivity and specificity values slightly lower than the 20-min assessment. These results highlight the 20-min assessment as the most reliable time point, offering a balance between high sensitivity and specificity. Nevertheless, the test remains accurate when conducted at shorter intervals.

The choice of assessment technique is also crucial for test accuracy. ICOS is the most accurate technique, with a sensitivity of 98.99% and a specificity of 98.55%. However, it is important to note that ICOS was evaluated in a single study[27], potentially limiting the generalizability of these results. To address this limitation, Isotope-ratio mass spectrometry is a more advisable option. In contrast, Infrared spectrometry, gas chromatography-mass spectrometry, isotope-ratio mass spectrometry, molecular correlation spectrometry, and Laser opto-galvanic effect spectroscopy yield varying levels of sensitivity and specificity. These findings underscore the significance of selecting the right assessment technique. While ICOS may be preferred when available due to its exceptional accuracy, other factors such as cost, availability, and local expertise should also be considered when making this choice.



### **<sup>14</sup>C-UBT performance: Urea dose, assessment timing, and measurement technique selection**

Our research indicates that the urea dosage utilized in the <sup>14</sup>C-UBT can also impact test accuracy. Specifically, a urea dose of 5 µCi was examined in four studies and was found to possess exceptional sensitivity (99.21%) and specificity (93.43%). These findings underscore the potential benefits of employing a 5 µCi dose for the <sup>14</sup>C-UBT, as it offers a high level of accuracy in detecting *H. pylori* infection. However, increasing the urea dose to 10 µCi, as investigated in a single study [28], resulted in a slightly lower sensitivity (96.72%) and a specificity of 80.00%. This suggests that while higher urea dosages may still provide reliable results, they may be associated with a decrease in specificity, which could lead to more false-positive results.

On the other hand, the use of 1 µCi of marked urea, which was the most commonly used dosage in 14 studies, resulted in a sensitivity of 96.78% and a specificity of 87.19%. This indicates that a 1 µCi dose remains a viable option for the <sup>14</sup>C-UBT, offering a good balance between sensitivity and specificity. Two recent studies using 0.75 µCi of urea reported a sensitivity of 88.94% and a specificity of 91.32%, suggesting that even lower urea doses can provide reasonable diagnostic accuracy [29,30].

Regarding the time for measurement, tests conducted 15 min after urea administration consistently exhibited the highest sensitivity (98.39%) and specificity (98.71%). This indicates that the 15-min time point is optimal for maximizing test accuracy. Tests conducted within 10 min post-administration maintained high sensitivity (97.83%) but had a somewhat lower specificity (79.90%). A single study conducted at 12.5 min post-administration reported favorable sensitivity (96.05%) and specificity (95.12%) [31]. In contrast, longer intervals (20, 25, and 30 min) showed more variability, with varying levels of sensitivity and specificity. This suggests that measurements taken beyond 15 min may not be as reliable for *H. pylori* detection. Clinicians should carefully consider the timing of the <sup>14</sup>C-UBT to ensure accurate results, with a preference for the 15-min mark when feasible.

Lastly, our analysis of assessment techniques uncovered differences in sensitivity and specificity. Liquid scintillation counting demonstrated the highest sensitivity (98.79%) but had a specificity of 87.24%. In contrast, Solid Scintillation UBT (scintillation counting) showed higher specificity (97.46%) at the expense of sensitivity (95.40%). The Heliprobe Analyser and Beta-scintillation counter also demonstrated moderate sensitivity and specificity. When choosing the assessment technique, the trade-off between sensitivity and specificity should be considered in relation to the clinical context. For instance, if high sensitivity is paramount to avoid missing positive cases, liquid scintillation counting may be the preferred method. Conversely, if high specificity is crucial to minimize false positives, solid scintillation counting could be a better choice.

### **Strengths and limitations**

This meta-analysis adhered to established guidelines and rigorous methodological principles, enhancing the validity and reliability of our findings. We used a bivariate random-effects model to calculate sensitivity, specificity, likelihood ratios, and the DOR, alongside generating SROC curves for a comprehensive statistical analysis of the included studies. Subgroup analyses based on urea dosing, measurement timing, and assessment technique were conducted to explore potential sources of variation, while Spearman correlation analysis was used to assess the threshold effect's impact on diagnostic accuracy. Additionally, we assessed publication bias through visual inspections of funnel plots and Egger's tests.

However, it's important to acknowledge inherent limitations in our analysis. These include potential language bias, reliance on available data, and challenges associated with the inherent heterogeneity in diagnostic accuracy studies. Although we did not impose language restrictions in our search, the inclusion of studies conducted in English, Spanish, or Portuguese may introduce language bias [32]. The exclusion of studies due to unavailability of full-text articles or articles not in these specified languages could potentially lead to the omission of essential data.

Furthermore, the quality of our meta-analysis is closely tied to the quality of the primary studies we included. Biases within these primary studies can affect our analysis outcomes. In particular, we have concerns regarding the inclusion of patients, as there was no reported consecutive patient inclusion in some studies, and the index test was not always performed using a pre-specified threshold. Moreover, the diversity in diagnostic accuracy studies can present challenges when consolidating results, and despite subgroup analyses, residual heterogeneity may impact the broad applicability of our findings. Encouragingly, the visual examination of the SROC curves indicates consistent accuracy assessments across the included studies. Nevertheless, it is imperative to underscore that the reliability of our meta-analysis hinges on the data provided in these included studies. The absence or inconsistency of critical data points can significantly affect the precision of our analysis. Researchers and clinicians should consider these strengths and limitations when applying our findings in their practice.

## **CONCLUSION**

In summary, our study offers crucial insights for selecting optimal diagnostic methods to detect *H. pylori* infection in clinical settings. We found that the <sup>13</sup>C-UBT outperforms the <sup>14</sup>C-UBT in terms of diagnostic accuracy, making it the preferred diagnostic approach. Furthermore, our findings highlight the significance of precise considerations when choosing urea dosage, assessment timing, and measurement techniques for both the <sup>13</sup>C-UBT and <sup>14</sup>C-UBT, thus enhancing diagnostic precision. These insights provide practical guidance to healthcare practitioners when choosing the most suitable diagnostic method for *H. pylori* infection, tailored to their specific clinical context. Factors like diagnostic accuracy, cost, and availability should be carefully weighed in this decision-making process. Our findings also have the potential to contribute significantly to the standardization of testing procedures, ensuring consistent and reliable results,

especially for patients with dyspepsia or suspected *H. pylori* infection. Nevertheless, it's essential for researchers and clinicians to consider the strengths and limitations when applying our findings in their practice.

## ARTICLE HIGHLIGHTS

### Research background

The urea breath test (UBT) has become a widely accepted non-invasive method for detecting *Helicobacter pylori* (*H. pylori*). While numerous studies have confirmed its high accuracy, its reliability is often hindered by inherent limitations.

### Research motivation

In a previous investigation, the diagnostic accuracy of the UBT, which encompasses both  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT, was evaluated in adult patients with dyspepsia to determine the presence of *H. pylori* infection. Although the test demonstrated a high degree of precision, its reliability was compromised by significant and unexplained heterogeneity, which persisted even after conducting subgroup analyses. This trend continued in subsequent studies, with similar challenges encountered in determining pooled estimates of diagnostic accuracy for  $^{14}\text{C}$ -UBT. Furthermore, a subsequent systematic review revealed that the variability in thresholds and reference standards across studies limited the available data for pooling accuracy measures at specific UBT thresholds. These findings underscore the need for a rigorous statistical synthesis to clarify and reconcile the diagnostic accuracy of the UBT for the diagnosis of *H. pylori* infection, addressing challenges identified in prior research.

### Research objectives

To evaluate and contrast the diagnostic accuracy of  $^{13}\text{C}$ -UBT and  $^{14}\text{C}$ -UBT for *H. pylori* infection in adult patients with dyspepsia.

### Research methods

We conducted independent searches of PubMed/MEDLINE, EMBASE, and Cochrane Central databases until April 2022, focusing on diagnostic accuracy studies that evaluated at least one of the index tests ( $^{13}\text{C}$ -UBT or  $^{14}\text{C}$ -UBT) against a reference standard. We utilized the QUADAS-2 tool to assess the methodological quality of the studies, and we calculated sensitivity, specificity, positive and negative test likelihood ratios (LR+ and LR-), as well as the diagnostic odds ratio (DOR) and their 95% confidence intervals using the bivariate random-effects model. We conducted subgroup analyses based on urea dosing, time after urea administration, and assessment technique. To investigate a possible threshold effect, we conducted Spearman correlation analysis, and we generated summary receiver operating characteristic (SROC) curves to assess heterogeneity. Lastly, we visually inspected a funnel plot and used Egger's test to evaluate publication bias.

### Research results

A screening of 4621 studies led to the selection of 60 articles for inclusion in a diagnostic test accuracy meta-analysis after full-text reading. Our analysis highlights the superior diagnostic accuracy of  $^{13}\text{C}$ -UBT compared to  $^{14}\text{C}$ -UBT, as evidenced by higher sensitivity (96.60% *vs* 96.15%), specificity (96.93% *vs* 89.84%), likelihood ratios (LR+ 22.00 *vs* 10.10; LR- 0.05 *vs* 0.06), and AUC values (0.979 *vs* 0.968). Particularly noteworthy is the significantly higher DOR of  $^{13}\text{C}$ -UBT (586.47) compared to  $^{14}\text{C}$ -UBT (DOR 226.50), establishing  $^{13}\text{C}$ -UBT as the preferred diagnostic tool for individuals with dyspepsia and *H. pylori* infection. Correlation analysis indicated no threshold effect for both  $^{13}\text{C}$ -UBT ( $r = 0.48$ ) and  $^{14}\text{C}$ -UBT ( $r = -0.01$ ), and the SROC curves consistently demonstrated accurate performance for both tests. The high AUC values ( $^{13}\text{C}$ -UBT: 0.979;  $^{14}\text{C}$ -UBT: 0.968), nearing 1.00, further affirm the excellent accuracy of both UBT variants, solidifying their reliability as diagnostic tools in clinical practice.

### Research conclusions

Our study establishes  $^{13}\text{C}$ -UBT as the superior diagnostic approach over  $^{14}\text{C}$ -UBT. Furthermore, our findings underscore the critical importance of meticulously considering factors such as urea dosage, assessment timing, and measurement techniques for both tests to optimize diagnostic accuracy. However, it is paramount for researchers and clinicians to thoroughly evaluate the strengths and limitations of our conclusions before integrating them into clinical practice.

### Research perspectives

Future research should focus on improving the comprehension, practicality, and dependability of UBTs for *H. pylori* infection. This endeavor involves refining techniques, examining sources of variability, exploring threshold effects, conducting longitudinal and comparative investigations, addressing biases, and assessing cost-effectiveness.

## FOOTNOTES

**Author contributions:** Lemos FFB, Castro CT, Silva Luz M, Queiroz DMM, and Freire de Melo F contributed to the conceptualization of the manuscript; Lemos FFB, Castro CT, Queiroz DMM and Freire de Melo F designed the study methodology; Lemos FFB, Castro CT,



Calmon MS, Silva Luz M, Rocha GR, Correa Santos GL, de Oliveira Silva LG, Calmon MS were responsible for manuscript visualization; Lemos FFB, Castro CT, Calmon MS, Silva Luz M, Rocha GR, Correa Santos GL, de Oliveira Silva LG, Calmon MS contributed to the investigation; Lemos FFB, Castro CT, Calmon MS, Silva Luz M, Rocha GR, Correa Santos GL, de Oliveira Silva LG, Calmon MS performed formal analysis; Lemos FFB and Castro CT wrote the original draft; Castro CT and Queiroz DMM were responsible for manuscript editing; Castro CT, Teixeira KN, Souza CL, and Queiroz DMM were responsible for manuscript writing and review; Freire de Melo F supervised the writing of the original draft.

**Supported by** Scientific Initiation Scholarship Programme (PIBIC) of the Bahia State Research Support Foundation; the Doctorate Scholarship Program of the Coordination of Improvement of Higher Education Personnel; the Scientific Initiation Scholarship Programme (PIBIC) of the National Council for Scientific and Technological Development; and the CNPq Research Productivity Fellowship.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Brazil

**ORCID number:** Fabian Fellipec Bueno Lemos 0000-0002-4686-7086; Caroline Tianeze de Castro 0000-0002-9445-8842; Marcel Silva Luz 0000-0003-1650-5807; Gabriel Reis Rocha 0000-0002-3090-0726; Gabriel Lima Correa Santos 0000-0003-3673-9889; Luis Guilherme de Oliveira Silva 0000-0001-7275-7182; Mariana Santos Calmon 0000-0002-3871-7408; Cláudio Lima Souza 0000-0002-8094-8357; Ana Carla Zarpelon-Schutz 0000-0002-8320-3633; Kádima Nayara Teixeira 0000-0002-2928-9181; Dulciene Maria de Magalhães Queiroz 0000-0003-1334-9423; Fabrício Freire de Melo 0000-0002-5680-2753.

**S-Editor:** Lin C

**L-Editor:** A

**P-Editor:** Zhao YQ

## REFERENCES

- Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of *Helicobacter pylori* infection between 1980 and 2022: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2023; **8**: 553-564 [PMID: 37086739 DOI: 10.1016/S2468-1253(23)00070-5]
- Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on *Helicobacter pylori* gastritis. *Gut* 2015; **64**: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]
- Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, Smith SI, Suerbaum S. *Helicobacter pylori* infection. *Nat Rev Dis Primers* 2023; **9**: 19 [PMID: 37081005 DOI: 10.1038/s41572-023-00431-8]
- Narayanan M, Reddy KM, Marsicano E. Peptic Ulcer Disease and *Helicobacter pylori* infection. *Mo Med* 2018; **115**: 219-224 [PMID: 30228726]
- Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, Ito H, Imoto I, Tanaka T, Tajika M, Niwa Y, Iwasaki Y, Aoi T, Hakozaiki N, Takata S, Suzuki K, Terao C, Hatakeyama M, Hirata M, Sugano K, Yoshida T, Kamatani Y, Nakagawa H, Matsuda K, Murakami Y, Spurdle AB, Matsuo K, Momozawa Y. *Helicobacter pylori*, Homologous-Recombination Genes, and Gastric Cancer. *N Engl J Med* 2023; **388**: 1181-1190 [PMID: 36988593 DOI: 10.1056/NEJMoa2211807]
- Lemos FFB, de Castro CT, Calmon MS, Silva Luz M, Pinheiro SLR, Faria Souza Mendes Dos Santos C, Correa Santos GL, Marques HS, Delgado HA, Teixeira KN, Souza CL, Oliveira MV, Freire de Melo F. Effectiveness of *Helicobacter pylori* eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis. *World J Gastroenterol* 2023; **29**: 2202-2221 [PMID: 37122607 DOI: 10.3748/wjg.v29.i14.2202]
- Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on *Helicobacter* and Microbiota (APAHAM). Screening and eradication of *Helicobacter pylori* for gastric cancer prevention: the Taipei global consensus. *Gut* 2020; **69**: 2093-2112 [PMID: 33004546 DOI: 10.1136/gutjnl-2020-322368]
- Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Ruge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European *Helicobacter* and Microbiota Study group. Management of *Helicobacter pylori* infection: the Maastricht VI/Florence consensus report. *Gut* 2022 [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745]
- Talebi Bezin Abadi A. Diagnosis of *Helicobacter pylori* Using Invasive and Noninvasive Approaches. *J Pathog* 2018; **2018**: 9064952 [PMID: 29951318 DOI: 10.1155/2018/9064952]
- Kayali S, Aloe R, Bonaguri C, Gaiani F, Manfredi M, Leandro G, Fornaroli F, Di Mario F, De' Angelis GL. Non-invasive tests for the diagnosis of *helicobacter pylori*: state of the art. *Acta Biomed* 2018; **89**: 58-64 [PMID: 30561419 DOI: 10.23750/abm.v89i8-S.7910]
- Sankararaman S, Moosavi L. Urea Breath Test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [PMID:

- 31194426]
- 12 **Savarino V**, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of *Helicobacter pylori* infection. *Gut* 1999; **45** Suppl 1: I18-I22 [PMID: 10457031 DOI: 10.1136/gut.45.2008.i18]
  - 13 **Leal YA**, Flores LL, Fuentes-Pananá EM, Cedillo-Rivera R, Torres J. 13C-urea breath test for the diagnosis of *Helicobacter pylori* infection in children: a systematic review and meta-analysis. *Helicobacter* 2011; **16**: 327-337 [PMID: 21762274 DOI: 10.1111/j.1523-5378.2011.00863.x]
  - 14 **Balon H**, Gold CA, Dworkin HJ, McCormick VA, Freitas JE. Procedure guideline for carbon-14-urea breath test. Society of Nuclear Medicine. *J Nucl Med* 1998; **39**: 2012-2014 [PMID: 9829599]
  - 15 **Balon HR**, Roff E. C-14-urea breath test: a new product and a word of caution. *J Nucl Med* 1998; **39**: 1306 [PMID: 9669416]
  - 16 **Ferwana M**, Abdulmajeed I, Alhajahmed A, Madani W, Firwana B, Hasan R, Altayar O, Limburg PJ, Murad MH, Knawy B. Accuracy of urea breath test in *Helicobacter pylori* infection: meta-analysis. *World J Gastroenterol* 2015; **21**: 1305-1314 [PMID: 25632206 DOI: 10.3748/wjg.v21.i4.1305]
  - 17 **Zhou Q**, Li L, Ai Y, Pan Z, Guo M, Han J. Diagnostic accuracy of the (14)C-urea breath test in *Helicobacter pylori* infections: a meta-analysis. *Wien Klin Wochenschr* 2017; **129**: 38-45 [PMID: 27848071 DOI: 10.1007/s00508-016-1117-3]
  - 18 **Best LM**, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for *Helicobacter pylori* infection. *Cochrane Database Syst Rev* 2018; **3**: CD012080 [PMID: 29543326 DOI: 10.1002/14651858.CD012080.pub2]
  - 19 **McInnes MDF**, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeftang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018; **319**: 388-396 [PMID: 29362800 DOI: 10.1001/jama.2017.19163]
  - 20 **Deeks JJ**, Bossuyt PM, Leeftang MM, Takwoingi Y. *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy*. 1st ed. New Jersey: John Wiley, 2023 [DOI: 10.1002/9781119756194]
  - 21 **Whiting PF**, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeftang MM, Sterne JA, Bossuyt PM; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011; **155**: 529-536 [PMID: 22007046 DOI: 10.7326/0003-4819-155-8-201110180-00009]
  - 22 **Reiman MP**, Thorborg K, Goode AP, Cook CE, Weir A, Hölmich P. Diagnostic Accuracy of Imaging Modalities and Injection Techniques for the Diagnosis of Femoroacetabular Impingement/Labral Tear: A Systematic Review With Meta-analysis. *Am J Sports Med* 2017; **45**: 2665-2677 [PMID: 28129509 DOI: 10.1177/0363546516686960]
  - 23 **Macaskill P**, Takwoingi Y, Deeks JJ, Gatsonis C. Understanding meta-analysis. In: *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy*. 1st ed. Deeks JJ, Bossuyt PM, Leeftang MM, Takwoingi Y, editors. New Jersey: John Wiley, 2023: 203-247 [DOI: 10.1002/9781119756194.ch9]
  - 24 **Kim KW**, Lee J, Choi SH, Huh J, Park SH. Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part I. General Guidance and Tips. *Korean J Radiol* 2015; **16**: 1175-1187 [PMID: 26576106 DOI: 10.3348/kjr.2015.16.6.1175]
  - 25 **Lee J**, Kim KW, Choi SH, Huh J, Park SH. Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part II. Statistical Methods of Meta-Analysis. *Korean J Radiol* 2015; **16**: 1188-1196 [PMID: 26576107 DOI: 10.3348/kjr.2015.16.6.1188]
  - 26 **Gatta L**, Ricci C, Tampieri A, Osborn J, Perna F, Bernabucci V, Vaira D. Accuracy of breath tests using low doses of 13C-urea to diagnose *Helicobacter pylori* infection: a randomised controlled trial. *Gut* 2006; **55**: 457-462 [PMID: 16162678 DOI: 10.1136/gut.2005.078626]
  - 27 **Som S**, Maity A, Banik GD, Ghosh C, Chaudhuri S, Daschakraborty SB, Ghosh S, Pradhan M. Excretion kinetics of 13C-urea breath test: influences of endogenous CO<sub>2</sub> production and dose recovery on the diagnostic accuracy of *Helicobacter pylori* infection. *Anal Bioanal Chem* 2014; **406**: 5405-5412 [PMID: 24939135 DOI: 10.1007/s00216-014-7951-0]
  - 28 **Novis BH**, Gabay G, Leichtmann G, Peri M, Bernheim J, Pomeranz IS. Two point analysis 15-minute 14C-urea breath test for diagnosing *Helicobacter pylori* infection. *Digestion* 1991; **50**: 16-21 [PMID: 1804728 DOI: 10.1159/000200735]
  - 29 **Wang X**, Zhang S, Chua EG, He Y, Li X, Liu A, Chen H, Wise MJ, Marshall BJ, Sun D, Tay CY. A re-testing range is recommended for (13)C- and (14)C-urea breath tests for *Helicobacter pylori* infection in China. *Gut Pathog* 2021; **13**: 38 [PMID: 34118962 DOI: 10.1186/s13099-021-00435-3]
  - 30 **Han YH**, Zhang W, Wang YT, Xiong ZJ, Du Q, Xie Y, Lu H. Performance evaluation of a novel 14C-urea breath test (solid scintillation) for the diagnosis of *Helicobacter pylori* infection. *Medicine (Baltimore)* 2023; **102**: e33107 [PMID: 36862867 DOI: 10.1097/MD.00000000000033107]
  - 31 **Gatta L**, Ricci C, Stanghellini V, Ali A, Menegatti M, Morselli Labate AM, Corinaldesi R, Miglioli M, Vaira D. Best cut-off values for [14C]-urea breath tests for *Helicobacter pylori* detection. *Scand J Gastroenterol* 2003; **38**: 1144-1148 [PMID: 14686717 DOI: 10.1080/00365520310006261]
  - 32 **Stern C**, Kleijnen J. Language bias in systematic reviews: you only get out what you put in. *JBIM Evid Synth* 2020; **18**: 1818-1819 [PMID: 32925418 DOI: 10.11124/JBIES-20-00361]
  - 33 **Alzoubi H**, Al-Mnayyis A, Al Rfoa I, Aql A, Abu-Lubad M, Hamdan O, Jaber K. The Use of (13)C-Urea Breath Test for Non-Invasive Diagnosis of *Helicobacter pylori* Infection in Comparison to Endoscopy and Stool Antigen Test. *Diagnostics (Basel)* 2020; **10** [PMID: 32635179 DOI: 10.3390/diagnostics10070448]
  - 34 **Nawacki L**, Czyż A, Bryk P, Kozieł D, Stępień R, Głuszek S. Can urea breath test (UBT) replace rapid urea test (RUT)? *Pol Przegl Chir* 2018; **90**: 44-48 [PMID: 30426947 DOI: 10.5604/01.3001.0012.0669]
  - 35 **Bruden DL**, Bruce MG, Miernyk KM, Morris J, Hurlburt D, Hennessy TW, Peters H, Sacco F, Parkinson AJ, McMahon BJ. Diagnostic accuracy of tests for *Helicobacter pylori* in an Alaska Native population. *World J Gastroenterol* 2011; **17**: 4682-4688 [PMID: 22180710 DOI: 10.3748/wjg.v17.i42.4682]
  - 36 **Peng NJ**, Lai KH, Lo GH, Hsu PI. Comparison of noninvasive diagnostic tests for *Helicobacter pylori* infection. *Med Princ Pract* 2009; **18**: 57-61 [PMID: 19060493 DOI: 10.1159/000163048]
  - 37 **Jordaan M**, Laurens JB. Diagnosis of *Helicobacter pylori* infection with the (13)C-urea breath test by means of GC-MS analysis. *J Sep Sci* 2008; **31**: 329-335 [PMID: 18196527 DOI: 10.1002/jssc.200700385]
  - 38 **Peng NJ**, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC, Tseng HH, Huang WK, Lo GH, Hsu PI. Capsule 13C-urea breath test for the diagnosis of *Helicobacter pylori* infection. *World J Gastroenterol* 2005; **11**: 1361-1364 [PMID: 15761976 DOI: 10.3748/wjg.v11.i9.1361]
  - 39 **Kato S**, Nakayama K, Minoura T, Konno M, Tajiri H, Matsuhisa T, Iinuma K; Japanese pediatric *Helicobacter* study group. Comparison

- between the 13C-urea breath test and stool antigen test for the diagnosis of childhood *Helicobacter pylori* infection. *J Gastroenterol* 2004; **39**: 1045-1050 [PMID: [15580396](#) DOI: [10.1007/s00535-004-1442-6](#)]
- 40 **Ohara S**, Kato M, Saito M, Fukuda S, Kato C, Hamada S, Nagashima R, Obara K, Suzuki M, Honda H, Asaka M, Toyota T. Comparison between a new 13C-urea breath test, using a film-coated tablet, and the conventional 13C-urea breath test for the detection of *Helicobacter pylori* infection. *J Gastroenterol* 2004; **39**: 621-628 [PMID: [15293131](#) DOI: [10.1007/s00535-004-1356-3](#)]
- 41 **Chen TS**, Chang FY, Chen PC, Huang TW, Ou JT, Tsai MH, Wu MS, Lin JT. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 2003; **18**: 1237-1243 [PMID: [14535979](#) DOI: [10.1046/j.1440-1746.2003.03139.x](#)]
- 42 **Valdepérez J**, Vicente R, Novella MP, Valle L, Sicilia B, Yus C, Gomollón F. [Is the breath test reliable in primary care diagnosis of *Helicobacter pylori* infection?]. *Aten Primaria* 2003; **31**: 93-97 [PMID: [12609106](#) DOI: [10.1016/s0212-6567\(03\)79144-6](#)]
- 43 **Gatta L**, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, Miglioli M, Vaira D. A rapid, low-dose, 13C-urea tablet for the detection of *Helicobacter pylori* infection before and after treatment. *Aliment Pharmacol Ther* 2003; **17**: 793-798 [PMID: [12641501](#) DOI: [10.1046/j.1365-2036.2003.01490.x](#)]
- 44 **Wong WM**, Lam SK, Lai KC, Chu KM, Xia HH, Wong KW, Cheung KL, Lin SK, Wong BC. A rapid-release 50-mg tablet-based 13C-urea breath test for the diagnosis of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2003; **17**: 253-257 [PMID: [12534410](#) DOI: [10.1046/j.1365-2036.2003.01417.x](#)]
- 45 **Ng FH**, Lai KC, Wong BC, Wong WM, Wong SY, Chow KC, Yuen ST, Leung SY, Lam SK. [13C]-urea breath test without prior fasting and without test meal is accurate for the detection of *Helicobacter pylori* infection in Chinese. *J Gastroenterol Hepatol* 2002; **17**: 834-838 [PMID: [12164957](#) DOI: [10.1046/j.1440-1746.2002.02833.x](#)]
- 46 **Wong WM**, Wong BC, Li TM, Wong KW, Cheung KL, Fung FM, Xia HH, Lam SK. Twenty-minute 50 mg 13C-urea breath test without test meal for the diagnosis of *Helicobacter pylori* infection in Chinese. *Aliment Pharmacol Ther* 2001; **15**: 1499-1504 [PMID: [11552925](#) DOI: [10.1046/j.1365-2036.2001.01078.x](#)]
- 47 **Wong BC**, Wong WM, Wang WH, Tang VS, Young J, Lai KC, Yuen ST, Leung SY, Hu WH, Chan CK, Hui WM, Lam SK. An evaluation of invasive and non-invasive tests for the diagnosis of *Helicobacter pylori* infection in Chinese. *Aliment Pharmacol Ther* 2001; **15**: 505-511 [PMID: [11284779](#) DOI: [10.1046/j.1365-2036.2001.00947.x](#)]
- 48 **Shirin H**, Kenet G, Shevah O, Wardi J, Birkenfeld S, Shahmurov M, Bruck R, Niv Y, Moss SF, Avni Y. Evaluation of a novel continuous real time (13)C urea breath analyser for *Helicobacter pylori*. *Aliment Pharmacol Ther* 2001; **15**: 389-394 [PMID: [11207514](#) DOI: [10.1046/j.1365-2036.2001.00926.x](#)]
- 49 **Pilotto A**, Franceschi M, Leandro G, Rassu M, Zagari RM, Bozzola L, Furlan F, Bazzoli F, Di Mario F, Valerio G. Noninvasive diagnosis of *Helicobacter pylori* infection in older subjects: comparison of the 13C-urea breath test with serology. *J Gerontol A Biol Sci Med Sci* 2000; **55**: M163-M167 [PMID: [10795730](#) DOI: [10.1093/gerona/55.3.m163](#)]
- 50 **Sheu BS**, Lee SC, Lin PW, Wang ST, Chang YC, Yang HB, Chuang CH, Lin XZ. Carbon urea breath test is not as accurate as endoscopy to detect *Helicobacter pylori* after gastrectomy. *Gastrointest Endosc* 2000; **51**: 670-675 [PMID: [10840298](#) DOI: [10.1067/mge.2000.105719](#)]
- 51 **Wong WM**, Wong BC, Wong KW, Fung FM, Lai KC, Hu WH, Yuen ST, Leung SY, Lau GK, Lai CL, Chan CK, Go R, Lam SK. (13)C-urea breath test without a test meal is highly accurate for the detection of *Helicobacter pylori* infection in Chinese. *Aliment Pharmacol Ther* 2000; **14**: 1353-1358 [PMID: [11012482](#) DOI: [10.1046/j.1365-2036.2000.00843.x](#)]
- 52 **Hahn M**, Fennerty MB, Corless CL, Magaret N, Lieberman DA, Faigel DO. Noninvasive tests as a substitute for histology in the diagnosis of *Helicobacter pylori* infection. *Gastrointest Endosc* 2000; **52**: 20-26 [PMID: [10882957](#) DOI: [10.1067/mge.2000.106686](#)]
- 53 **Chen X**, Haruma K, Kamada T, Mihara M, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Factors that affect results of the 13C urea breath test in Japanese patients. *Helicobacter* 2000; **5**: 98-103 [PMID: [10849059](#) DOI: [10.1046/j.1523-5378.2000.00015.x](#)]
- 54 **Peng NJ**, Hsu PI, Lee SC, Tseng HH, Huang WK, Tsay DG, Ger LP, Lo GH, Lin CK, Tsai CC, Lai KH. A 15-minute [13C]-urea breath test for the diagnosis of *Helicobacter pylori* infection in patients with non-ulcer dyspepsia. *J Gastroenterol Hepatol* 2000; **15**: 284-289 [PMID: [10764029](#) DOI: [10.1046/j.1440-1746.2000.02159.x](#)]
- 55 **Riepl RL**, Folwaczny C, Otto B, Klausner A, Blendinger C, Wiebecke B, König A, Lehnert P, Heldwein W. Accuracy of 13C-urea breath test in clinical use for diagnosis of *Helicobacter pylori* infection. *Z Gastroenterol* 2000; **38**: 13-19 [PMID: [10689743](#) DOI: [10.1055/s-2000-15278](#)]
- 56 **D'Elia MM**, Amedei A, Benagiano M, Azzurri A, Del Prete G. Usefulness of (13)C-urea breath test in the diagnosis of gastric *helicobacter pylori* infection. *Int J Immunopathol Pharmacol* 2000; **13**: 27-30 [PMID: [12749775](#) DOI: [10.1177/039463200001300104](#)]
- 57 **van der Hulst RW**, Hensen EF, van der Ende A, Kruizinga SP, Homan A, Tytgat GN. [Laser-assisted 13C-urea breath test; a new noninvasive detection method for *Helicobacter pylori* infection]. *Ned Tijdschr Geneesk* 1999; **143**: 400-404 [PMID: [10221110](#)]
- 58 **Leodolter A**, Domínguez-Muñoz JE, Von Arnim U, Malfertheiner P. Citric acid or orange juice for the 13C-urea breath test: the impact of pH and gastric emptying. *Aliment Pharmacol Ther* 1999; **13**: 1057-1062 [PMID: [10468681](#) DOI: [10.1046/j.1365-2036.1999.00557.x](#)]
- 59 **Mock T**, Yatscoff R, Foster R, Hyun JH, Chung IS, Shim CS, Yacyshyn B. Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of *Helicobacter pylori* infection. *Clin Biochem* 1999; **32**: 59-63 [PMID: [10074893](#) DOI: [10.1016/s0009-9120\(98\)00082-4](#)]
- 60 **Perri F**, Clemente R, Festa V, Quitadamo M, Conoscitore P, Niro G, Ghos Y, Rutgeerts P, Andriulli A. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of *Helicobacter pylori* infection. *Ital J Gastroenterol Hepatol* 1998; **30**: 146-150 [PMID: [9675647](#)]
- 61 **Ohara S**, Kato M, Asaka M, Toyota T. The UBiT-100 13CO<sub>2</sub> infrared analyzer: comparison between infrared spectrometric analysis and mass spectrometric analysis. *Helicobacter* 1998; **3**: 49-53 [PMID: [9546118](#) DOI: [10.1046/j.1523-5378.1998.08046.x](#)]
- 62 **Leodolter A**, Domínguez-Muñoz JE, von Arnim U, Manes G, Malfertheiner P. 13C-urea breath test for the diagnosis of *Helicobacter pylori* infection. A further simplification for clinical practice. *Scand J Gastroenterol* 1998; **33**: 267-270 [PMID: [9580391](#) DOI: [10.1080/00365529850170847](#)]
- 63 **Andersen LP**, Kiilerick S, Pedersen G, Thoreson AC, Jørgensen F, Rath J, Larsen NE, Børup O, Krogfelt K, Scheibel J, Rune S. An analysis of seven different methods to diagnose *Helicobacter pylori* infections. *Scand J Gastroenterol* 1998; **33**: 24-30 [PMID: [9489904](#) DOI: [10.1080/00365529850166167](#)]
- 64 **Ellenrieder V**, Glasbrenner B, Stoffels C, Weiler S, Bode G, Möller P, Adler G. Qualitative and semi-quantitative value of a modified 13C-urea breath test for identification of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 1997; **9**: 1085-1089 [PMID: [9431899](#) DOI: [10.1097/00042737-199711000-00011](#)]
- 65 **Epple HJ**, Kirstein FW, Bojarski C, Frege J, Fromm M, Riecken EO, Schulzke JD. 13C-urea breath test in *Helicobacter pylori* diagnosis and eradication. Correlation to histology, origin of 'false' results, and influence of food intake. *Scand J Gastroenterol* 1997; **32**: 308-314 [PMID: [9431899](#) DOI: [10.1097/00042737-199711000-00011](#)]

- 9140151 DOI: [10.3109/00365529709007677](https://doi.org/10.3109/00365529709007677)]
- 66 **Labenz J**, Bärsh G, Peitz U, Aygen S, Hennemann O, Tillenburger B, Becker T, Stolte M. Validity of a novel biopsy urease test (HUT) and a simplified 13C-urea breath test for diagnosis of Helicobacter pylori infection and estimation of the severity of gastritis. *Digestion* 1996; **57**: 391-397 [PMID: [8913700](https://pubmed.ncbi.nlm.nih.gov/8913700/) DOI: [10.1159/000201366](https://doi.org/10.1159/000201366)]
  - 67 **Logan RP**, Polson RJ, Misiewicz JJ, Rao G, Karim NQ, Newell D, Johnson P, Wadsworth J, Walker MM, Baron JH. Simplified single sample 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. *Gut* 1991; **32**: 1461-1464 [PMID: [1773948](https://pubmed.ncbi.nlm.nih.gov/1773948/) DOI: [10.1136/gut.32.12.1461](https://doi.org/10.1136/gut.32.12.1461)]
  - 68 **Dill S**, Payne-James JJ, Misiewicz JJ, Grimble GK, McSwiggan D, Pathak K, Wood AJ, Scrimgeour CM, Rennie MJ. Evaluation of 13C-urea breath test in the detection of Helicobacter pylori and in monitoring the effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia. *Gut* 1990; **31**: 1237-1241 [PMID: [2253905](https://pubmed.ncbi.nlm.nih.gov/2253905/) DOI: [10.1136/gut.31.11.1237](https://doi.org/10.1136/gut.31.11.1237)]
  - 69 **Miftahussurur M**. Noninvasive Helicobacter pylori Diagnostic Methods in Indonesia. *Gut Liver* 2020; **14**: 553-559 [PMID: [31693853](https://pubmed.ncbi.nlm.nih.gov/31693853/) DOI: [10.5009/gnl19264](https://doi.org/10.5009/gnl19264)]
  - 70 **Cosgun Y**, Yildirim A, Yucel M, Karakoc AE, Koca G, Gonultas A, Gursay G, Ustun H, Korkmaz M. Evaluation of Invasive and Noninvasive Methods for the Diagnosis of Helicobacter Pylori Infection. *Asian Pac J Cancer Prev* 2016; **17**: 5265-5272 [PMID: [28125872](https://pubmed.ncbi.nlm.nih.gov/28125872/) DOI: [10.22034/APJCP.2016.17.12.5265](https://doi.org/10.22034/APJCP.2016.17.12.5265)]
  - 71 **Atli T**, Sahin S, Arslan BU, Varli M, Yalcin AE, Aras S. Comparison of the C14 urea breath test and histopathology in the diagnosis of Helicobacter pylori in the elderly. *J Pak Med Assoc* 2012; **62**: 1061-1065 [PMID: [23866448](https://pubmed.ncbi.nlm.nih.gov/23866448/)]
  - 72 **Alarcón-Rivera G**, Vázquez-Jiménez G, de la Cruz-Patiño E, Abarca M, Leyva E, Delgado F, Ruíz-Juárez I, Grube-Pagola P, Roesch-Dietlen F, Remes-Troche JM. [Comparative analysis between breath test, serological immunoassay and rapid-urease test for detection of Helicobacter pylori infection in Mexican patients with non-investigated dyspepsia]. *Rev Gastroenterol Mex* 2011; **76**: 322-329 [PMID: [22188957](https://pubmed.ncbi.nlm.nih.gov/22188957/)]
  - 73 **Mansour-Ghanaei F**, Sanaei O, Joukar F. Clinical Validation of an Office-Based C-UBT (Heliprobe) for H. pylori Diagnosis in Iranian Dyspeptic Patients. *Gastroenterol Res Pract* 2011; **2011**: 930941 [PMID: [21760778](https://pubmed.ncbi.nlm.nih.gov/21760778/) DOI: [10.1155/2011/930941](https://doi.org/10.1155/2011/930941)]
  - 74 **Ozdemir E**, Karabacak NI, Degertekin B, Cirak M, Dursun A, Engin D, Unal S, Unlü M. Could the simplified (14)C urea breath test be a new standard in noninvasive diagnosis of Helicobacter pylori infection? *Ann Nucl Med* 2008; **22**: 611-616 [PMID: [18756364](https://pubmed.ncbi.nlm.nih.gov/18756364/) DOI: [10.1007/s12149-008-0168-6](https://doi.org/10.1007/s12149-008-0168-6)]
  - 75 **Rasool S**, Abid S, Jaffri W. Validity and cost comparison of 14carbon urea breath test for diagnosis of H Pylori in dyspeptic patients. *World J Gastroenterol* 2007; **13**: 925-929 [PMID: [17352025](https://pubmed.ncbi.nlm.nih.gov/17352025/) DOI: [10.3748/wjg.v13.i6.925](https://doi.org/10.3748/wjg.v13.i6.925)]
  - 76 **Gurbuz AK**, Ozel AM, Narin Y, Yazgan Y, Baloglu H, Demirturk L. Is the remarkable contradiction between histology and 14C urea breath test in the detection of Helicobacter pylori due to false-negative histology or false-positive 14C urea breath test? *J Int Med Res* 2005; **33**: 632-640 [PMID: [16372580](https://pubmed.ncbi.nlm.nih.gov/16372580/) DOI: [10.1177/147323000503300604](https://doi.org/10.1177/147323000503300604)]
  - 77 **González P**, Galleguillos C, Massardo T, Rivera M, Morales A, Smok G, Moyano L, Pimentel C, Alay R, Otárola S. Could the [14C]urea breath test be proposed as a 'gold standard' for detection of Helicobacter pylori infection? *Med Sci Monit* 2003; **9**: CR363-CR368 [PMID: [12942033](https://pubmed.ncbi.nlm.nih.gov/12942033/)]
  - 78 **Oztürk E**, Yeşilova Z, Ilgan S, Ozgüven M, Dağalp K. Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment. *J Gastroenterol Hepatol* 2009; **24**: 1248-1251 [PMID: [19486449](https://pubmed.ncbi.nlm.nih.gov/19486449/) DOI: [10.1111/j.1440-1746.2009.05845.x](https://doi.org/10.1111/j.1440-1746.2009.05845.x)]
  - 79 **Gomes AT**, Coelho LK, Secaf M, Módena JL, Troncon LE, Oliveira RB. Accuracy of the 14C-urea breath test for the diagnosis of Helicobacter pylori. *Sao Paulo Med J* 2002; **120**: 68-71 [PMID: [12163895](https://pubmed.ncbi.nlm.nih.gov/12163895/) DOI: [10.1590/s1516-31802002000300002](https://doi.org/10.1590/s1516-31802002000300002)]
  - 80 **Desroches JJ**, Lahaie RG, Picard M, Morais J, Dumont A, Gaudreau C, Picard D, Chartrand R. Methodological validation and clinical usefulness of carbon-14-urea breath test for documentation of presence and eradication of Helicobacter pylori infection. *J Nucl Med* 1997; **38**: 1141-1145 [PMID: [9225808](https://pubmed.ncbi.nlm.nih.gov/9225808/)]
  - 81 **Allardye RA**, Chapman BA, Tie AB, Burt MJ, Yeo KJ, Keenan JI, Bagshaw PF. 37 kBq 14C-urea breath test and gastric biopsy analyses of H. pylori infection. *Aust N Z J Surg* 1997; **67**: 31-34 [PMID: [9033373](https://pubmed.ncbi.nlm.nih.gov/9033373/) DOI: [10.1111/j.1445-2197.1997.tb01890.x](https://doi.org/10.1111/j.1445-2197.1997.tb01890.x)]
  - 82 **Faigel DO**, Childs M, Furth EE, Alavi A, Metz DC. New noninvasive tests for Helicobacter pylori gastritis. Comparison with tissue-based gold standard. *Dig Dis Sci* 1996; **41**: 740-748 [PMID: [8674395](https://pubmed.ncbi.nlm.nih.gov/8674395/) DOI: [10.1007/BF02213130](https://doi.org/10.1007/BF02213130)]
  - 83 **Goh KL**, Parasakthi N, Peh SC, Ong KK. 14C-urea breath test: a useful non-invasive test in the diagnosis of Helicobacter pylori infection. *Med J Malaysia* 1995; **50**: 208-211 [PMID: [8926896](https://pubmed.ncbi.nlm.nih.gov/8926896/)]
  - 84 **Kao CH**, Huang CK, Wang SJ, Hsu CY, Lin WY, Chen GH. Accuracy of a rapid 10-minute carbon-14 urea breath test for the diagnosis of Helicobacter pylori-associated peptic ulcer disease. *Eur J Nucl Med* 1993; **20**: 708-711 [PMID: [8404959](https://pubmed.ncbi.nlm.nih.gov/8404959/) DOI: [10.1007/BF00181763](https://doi.org/10.1007/BF00181763)]
  - 85 **Vivas J**, Contreras M, Mathew C, Peraza S, Maury de Tami I, Oliver W, Cano E, Castro D, Andrade O, Sanchez V. [The use of urea carbon 14 in breath tests as diagnostic method for Helicobacter pylori infections]. *G E N* 1993; **47**: 150-156 [PMID: [8112551](https://pubmed.ncbi.nlm.nih.gov/8112551/)]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

